EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hyperferritinemia Screening to Aid Identification and Differentiation of Patients with Hyperinflammatory Disorders

Hallie A Carol, Adam S Mayer, Michael S Zhang, Vinh Dang, Jemy Varghese, Zachary Martinez, Corinne Schneider, Joy Elizabeth Baker, Paul Tsoukas, Edward M Behrens, Randy Q Cron, Caroline Diorio und 5 weitere

Journal of Clinical Immunology · 2025-12 · 45 (1)

DOI: 10.1007/s10875-024-01797-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Immunology, online erschienen am 12.09.2024. Verfasst von Hallie A Carol und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Biomarkers, Interleukin-18, Hyperferritinemia. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NICHD NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High ferritin is an important and sensitive biomarker for the various forms of hemophagocytic lymphohistiocytosis (HLH), a diverse and deadly group of cytokine storm syndromes. Early action to prevent immunopathology in HLH often includes empiric immunomodulation, which can complicate etiologic work-up and prevent collection of early/pre-treatment research samples. To address this, we instituted an alert system at UPMC Children’s Hospital where serum ferritin > 1000 ng/mL triggered real-time chart review, assessment of whether the value reflected “inflammatory hyperferritnemia (IHF)”, and biobanking of remnant samples from consenting IHF patients. We extracted relevant clinical data; periodically measured serum total IL-18, IL-18 binding protein (IL-18BP), and CXCL9; retrospectively classified patients by etiology into infectious, rheumatic, or immune dysregulation; and subjected a subgroup of samples to a 96-analyte biomarker screen. 180 patients were identified, 30.5% of which had IHF. Maximum ferritin levels were significantly higher in patients with IHF than with either hemoglobinopathy or transplant, and highly elevated total IL-18 levels were distinctive to patients with Stills Disease and/or Macrophage Activation Syndrome (MAS). Multi-analyte analysis showed elevation in proteins associated with cytotoxic lymphocytes in all IHF samples when compared to healthy controls and depression of proteins such as ANGPT1 and VEGFR2 in samples from hyperferritinemic sepsis patients relative to non-sepsis controls. This real-time IFH screen proved feasible and efficient, validated prior observations about the specificity of IL-18, enabled early sample collection from a complex population, suggested a unique vascular biomarker signature in hyperferritinemic sepsis, and expanded our understanding of IHF heterogeneity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphohistiocytosis, HemophagocyticBiomarkersInterleukin-18HyperferritinemiaFerritinsHumansFemaleMaleChildChild, PreschoolInfantAdolescentDiagnosis, DifferentialIntercellular Signaling Peptides and ProteinsChemokine CXCL9InflammationRetrospective Studies

Stichwörter der Autor:innen

Hemophagocytic lymphohistiocytosis (HLH)HyperferritinemiaHyperinflammatory disordersInterleukin-18Macrophage activation syndrome (MAS)

Substanzen

BiomarkersInterleukin-18Ferritinsinterleukin-18 binding proteinIntercellular Signaling Peptides and ProteinsChemokine CXCL9CXCL9 protein, human

Autor:innen und Institutionen

  • Division of Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Division of Pediatric Allergy/Immunology, University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • RK Mellon Institute for Pediatric Research & Pediatric Rheumatology, University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Division of Pediatric Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Förderung

  • NIAMS NIH HHS
  • NICHD NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS
  • Paul Calabresi K12 Career Development Award
  • NIGMS NIH HHS
  • National Institute of Child Health and Human Development
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Carol, H. A., Mayer, A. S., Zhang, M. S., Dang, V., Varghese, J., Martinez, Z., Schneider, C., Baker, J. E., Tsoukas, P., Behrens, E. M., Cron, R. Q., Diorio, C., Henderson, L. A., Schulert, G., Lee, P., Kernan, K. F., & Canna, S. W. (2025). Hyperferritinemia Screening to Aid Identification and Differentiation of Patients with Hyperinflammatory Disorders. Journal of Clinical Immunology, 45(1). https://doi.org/10.1007/s10875-024-01797-4

Vancouver

Carol HA, Mayer AS, Zhang MS, Dang V, Varghese J, Martinez Z, et al. Hyperferritinemia Screening to Aid Identification and Differentiation of Patients with Hyperinflammatory Disorders. Journal of Clinical Immunology. 2025;45(1). doi:10.1007/s10875-024-01797-4

BibTeX
@article{Carol2025,
  author = {Carol, Hallie A and Mayer, Adam S and Zhang, Michael S and Dang, Vinh and Varghese, Jemy and Martinez, Zachary and Schneider, Corinne and Baker, Joy Elizabeth and Tsoukas, Paul and Behrens, Edward M and Cron, Randy Q and Diorio, Caroline and Henderson, Lauren A and Schulert, Grant and Lee, Pui and Kernan, Kate F and Canna, Scott W},
  title = {Hyperferritinemia Screening to Aid Identification and Differentiation of Patients with Hyperinflammatory Disorders},
  journal = {Journal of Clinical Immunology},
  year = {2025},
  volume = {45},
  number = {1},
  doi = {10.1007/s10875-024-01797-4}
}
Kostenlos starten →